Sign up
Pharma Capital

ANGLE device central to new, ground-breaking cancer research

Scientists at the University of Basel, Switzerland, used ANGLE’s Parsortix liquid biopsy to isolate metastatic circulating tumour cell clusters
cancer cells from taken by an electron microscope
The work may ultimately help prevent the spread of the killer disease, a process called metastasis

ANGLE PLC (LON:AGL) has revealed its cancer detection device played an important role in research that may one day help prevent the spread of cancer around the body.

Scientists at the University of Basel, Switzerland, used ANGLE’s Parsortix liquid biopsy to isolate metastatic circulating tumour cell clusters - a group of cancer and other cells tethered together as a single mass.

WATCH: ANGLE plc's Parsortix device plays critical role in ground-breaking new cancer research

Once these clusters were identified, the Basel team, led by Professor Nicola Aceto, was able to treat them with repurposed drugs already on the market.

Eye-catching

Eye-catching was the fact that this approach led to a “near total elimination” of metastasis in animal models.

As most people will know, metastasis is where cancer spreads to other parts of the body via the bloodstream. It is responsible for more than 90% of all cancer-related deaths.  

The detail of the research undertaken by the Cancer Metastasis Laboratory was published Friday (Jan 11) as a peer-reviewed article in the prestigious journal, Cell.

ANGLE is seeking US Food & Drug Administration approval for Parsortix.

Ground-breaking

Chief executive, Andrew Newland, said: "The ground-breaking CTC cluster work undertaken over the last three years by the University of Basel, one of ANGLE's leading customers, highlights completely new clinical uses for the Parsortix system with the potential to play a central role in dramatically improving patient outcomes.

“This is a key potential application for Parsortix liquid biopsy once we receive FDA clearance.

“Our ultimate aim is for the Parsortix system to be routinely used for all cancer patients in the future."

---Repeated from Thursday evening---

Ian_55ae0ddd437b7.jpg
Why Invest In ANGLE PLC? Read More Here

Register here to be notified of future AGL Company articles
View full AGL profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.